Reports
Global Haematologic Malignancies Treatment Market Analysis: By Type: Leukaemia, Lymphoma, Multiple Myaeloma, Others; By Therapy: Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation, Others; Regional Analysis; Market Dynamics: SWOT Analysis, Porter’s Five Forces Analysis; Competitive Landscape; 2024-2032
Global Haematologic Malignancies Treatment Market Outlook
The global haematologic malignancies treatment market reached a value of USD 63.62 billion in 2023. The market is further expected to grow at a CAGR of 10.5% in the forecast period of 2024-2032 to reach a value of USD 115.75 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Growing Demand for Chemotherapy to Augment the Haematologic Malignancies Treatment Industry Growth
Based on therapy, the chemotherapy segment accounts for a significant share in the haematologic malignancies treatment industry and is expected to grow further at a healthy pace over the forecast period. Chemotherapy is a treatment for various blood cancers that involves the use of a mixture of medicines to fight cancer cells by preventing them from multiplying and developing. Chemotherapy reduces tumours and allows surgical excision of cancer in people with malignancies that are only marginally resectable. Over the forecast period, this is likely to drive the revenue growth in the chemotherapy segment.
Asia Pacific to Provide Enhanced Growth Opportunities to the Hematologic Malignancies Treatment Industry
Region-wise, Asia Pacific is expected to witness a robust growth over the forecast period and hold a significant share of the market by 2026. The rapid development of advanced healthcare facilities, the rising incidences of blood cancer, increased awareness of early diagnostic and treatment approaches, and a growing focus on meeting unmet clinical needs of patients in countries throughout the region are the major factors that are expected to contribute to the growth of the haematologic malignancies treatment industry in the region.
Haematologic Malignancies Treatment: Market Segmentation
Cancers of the blood, bone marrow, and lymph nodes are known as haematologic malignancies. Acute lymphocytic leukaemia (ALL), chronic lymphocytic leukaemia (CLL), acute myeloid leukaemia (AML), chronic myeloid leukaemia (CML), myeloma, and lymphoma (Hodgkin's and non-Hodgkin’s (NHL)) are all included in this categorisation. The commonly suggested treatment methods for haematologic malignancies are chemotherapy, radiotherapy, immunotherapy, and stem cell transplantation, among others.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
By type, the market is divided into:
- Leukaemia
- Lymphoma
- Multiple Myaeloma
- Others
Among these, the leukaemia segment is further classified based on type into acute lymphocytic leukaemia, chronic lymphocytic leukaemia, acute myeloid leukaemia, and chronic myeloid leukaemia.
Based on therapy, the industry can be segmented into:
- Chemotherapy
- Radiotherapy
- Immunotherapy
- Stem Cell Transplantation
- Others
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Growing Prevalence of Haematologic Malignancies to Bolster the Growth of the Hematologic Malignancies Treatment Industry
The haematologic malignancies treatment industry is seeing a healthy growth due to the rising number of incidences of haematologic malignancies. Moreover, rising investment in the development of physiologically effective medicines, as well as a favourable reimbursement scenario, are fuelling the market growth. Furthermore, the market expansion is being propelled by substantial research and development efforts, a robust product pipeline, and a rising number of product releases over the years.
Over the forecast period, the rapidly growing geriatric population throughout the world is expected to be a key driver of the market growth because the elderly are at a greater risk of haematologic malignancies.
Key Industry Players in the Global Haematologic Malignancies Treatment Market
The report gives a detailed analysis of the following key players in the global haematologic malignancies treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- Sanofi
- AbbVie Inc.
- Novartis AG
- Others
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2023 |
| Historical Period | 2018-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Type, Therapy, Region |
| Breakup by Type | Leukaemia, Lymphoma, Multiple Myaeloma, Others |
| Breakup by Therapy | Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation, Others |
| Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | Pfizer Inc., F.Hoffman-LA Roche Ltd., Sanofi, AbbVie Inc., Novartis AG, Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Haematologic Malignancies Treatment Market Analysis
8.1 Key Industry Highlights
8.2 Global Haematologic Malignancies Treatment Historical Market (2018-2023)
8.3 Global Haematologic Malignancies Treatment Market Forecast (2024-2032)
8.4 Global Haematologic Malignancies Treatment Market by Type
8.4.1 Leukaemia
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2018-2023)
8.4.1.3 Forecast Trend (2024-2032)
8.4.1.4 Breakup by Type
8.4.1.4.1 Acute Lymphocytic Leukaemia
8.4.1.4.1.1 Market Share
8.4.1.4.1.2 Historical Trend (2018-2023)
8.4.1.4.1.3 Forecast Trend (2024-2032)
8.4.1.4.2 Chronic Lymphocytic Leukaemia
8.4.1.4.2.1 Market Share
8.4.1.4.2.2 Historical Trend (2018-2023)
8.4.1.4.2.3 Forecast Trend (2024-2032)
8.4.1.4.3 Acute Myeloid Leukaemia
8.4.1.4.3.1 Market Share
8.4.1.4.3.2 Historical Trend (2018-2023)
8.4.1.4.3.3 Forecast Trend (2024-2032)
8.4.1.4.4 Chronic Myeloid Leukaemia
8.4.1.4.4.1 Market Share
8.4.1.4.4.2 Historical Trend (2018-2023)
8.4.1.4.4.3 Forecast Trend (2024-2032)
8.4.2 Lymphoma
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2018-2023)
8.4.2.3 Forecast Trend (2024-2032)
8.4.3 Multiple Myaeloma
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2024-2032)
8.4.3.3 Forecast Trend (2024-2032)
8.4.4 Others
8.5 Global Haematologic Malignancies Treatment Market by Therapy
8.5.1 Chemotherapy
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2018-2023)
8.5.1.3 Forecast Trend (2024-2032)
8.5.2 Radiotherapy
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2018-2023)
8.5.2.3 Forecast Trend (2024-2032)
8.5.3 Immunotherapy
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2018-2023)
8.5.3.3 Forecast Trend (2024-2032)
8.5.4 Stem Cell Transplantation
8.5.4.1 Market Share
8.5.4.2 Historical Trend (2018-2023)
8.5.4.3 Forecast Trend (2024-2032)
8.5.5 Others
8.6 Global Haematologic Malignancies Treatment Market by Region
8.6.1 Market Share
8.6.1.1 North America
8.6.1.2 Europe
8.6.1.3 Asia Pacific
8.6.1.4 Latin America
8.6.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2018-2023)
9.1.2 Forecast Trend (2024-2032)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2018-2023)
9.2.2 Forecast Trend (2024-2032)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2018-2023)
9.3.2 Forecast Trend (2024-2032)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2018-2023)
9.4.2 Forecast Trend (2024-2032)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2018-2023)
9.5.2 Forecast Trend (2024-2032)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Competitive Landscape
11.1 Market Structure
11.2 Company Profiles
11.2.1 Pfizer Inc.
11.2.1.1 Company Overview
11.2.1.2 Product Portfolio
11.2.1.3 Demographic Reach and Achievements
11.2.1.4 Certifications
11.2.2 F.Hoffman-LA Roche Ltd.
11.2.2.1 Company Overview
11.2.2.2 Product Portfolio
11.2.2.3 Demographic Reach and Achievements
11.2.2.4 Certifications
11.2.3 Sanofi
11.2.3.1 Company Overview
11.2.3.2 Product Portfolio
11.2.3.3 Demographic Reach and Achievements
11.2.3.4 Certifications
11.2.4 AbbVie Inc.
11.2.4.1 Company Overview
11.2.4.2 Product Portfolio
11.2.4.3 Demographic Reach and Achievements
11.2.4.4 Certifications
11.2.5 Novartis AG
11.2.5.1 Company Overview
11.2.5.2 Product Portfolio
11.2.5.3 Demographic Reach and Achievements
11.2.5.4 Certifications
11.2.6 Others
12 Industry Events and Developments
List of Key Figures and Tables
1. Global Haematologic Malignancies Treatment Market: Key Industry Highlights, 2018 and 2032
2. Global Haematologic Malignancies Treatment Historical Market: Breakup by Type (USD Billion), 2018-2023
3. Global Haematologic Malignancies Treatment Market Forecast: Breakup by Type (USD Billion), 2024-2032
4. Global Haematologic Malignancies Treatment Historical Market: Breakup by Therapy (USD Billion), 2018-2023
5. Global Haematologic Malignancies Treatment Market Forecast: Breakup by Therapy (USD Billion), 2024-2032
6. Global Haematologic Malignancies Treatment Historical Market: Breakup by Region (USD Billion), 2018-2023
7. Global Haematologic Malignancies Treatment Market Forecast: Breakup by Region (USD Billion), 2024-2032
8. North America Haematologic Malignancies Treatment Historical Market: Breakup by Country (USD Billion), 2018-2023
9. North America Haematologic Malignancies Treatment Market Forecast: Breakup by Country (USD Billion), 2024-2032
10. Europe Haematologic Malignancies Treatment Historical Market: Breakup by Country (USD Billion), 2018-2023
11. Europe Haematologic Malignancies Treatment Market Forecast: Breakup by Country (USD Billion), 2024-2032
12. Asia Pacific Haematologic Malignancies Treatment Historical Market: Breakup by Country (USD Billion), 2018-2023
13. Asia Pacific Haematologic Malignancies Treatment Market Forecast: Breakup by Country (USD Billion), 2024-2032
14. Latin America Haematologic Malignancies Treatment Historical Market: Breakup by Country (USD Billion), 2018-2023
15. Latin America Haematologic Malignancies Treatment Market Forecast: Breakup by Country (USD Billion), 2024-2032
16. Middle East and Africa Haematologic Malignancies Treatment Historical Market: Breakup by Country (USD Billion), 2018-2023
17. Middle East and Africa Haematologic Malignancies Treatment Market Forecast: Breakup by Country (USD Billion), 2024-2032
18. Global Haematologic Malignancies Treatment Market Structure
Key Questions Answered in the Report
In 2023, the global haematologic malignancies treatment market attained a value of nearly USD 63.62 billion.
The market is projected to grow at a CAGR of 10.5% between 2024 and 2032.
The market is estimated to witness a healthy growth in the forecast period of 2024-2032 to reach USD 115.75 billion by 2032.
The major drivers of the industry, such as the growing prevalence of hematologic malignancies, the growing R&D investment, and the increasing geriatric population, are expected to aid the market growth.
The key market trends guiding the growth of the industry include the favourable reimbursement scenario.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The major types of haematologic malignancies in the market are leukaemia, lymphoma, and multiple myaeloma, among others.
The significant therapies in the industry are chemotherapy, radiotherapy, immunotherapy, and stem cell transplantation, among others.
The major players in the industry are Pfizer Inc., F. Hoffmann-La Roche Ltd., Sanofi, AbbVie Inc., and Novartis AG, among others.
Analyst Review
The global haematologic malignancies treatment market attained a value of USD 63.62 billion in 2023, driven by the rising prevalence of hematologic malignancies. Aided by the increasing R&D investment, the market is expected to witness a further growth in the forecast period of 2024-2032, growing at a CAGR of 10.5%. The market is projected to reach USD 115.75 billion by 2032.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. The market based on type can be divided into leukaemia, lymphoma, multiple myaeloma, and others. Among these, the leukemia segment is further classified based on type into acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and chronic myeloid leukemia. By therapy, the industry can be divided into chemotherapy, radiotherapy, immunotherapy, stem cell transplantation, and others. The major regional markets for haematologic malignancies treatment are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Sanofi, AbbVie Inc., Novartis AG, and others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$2799
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER